{"id":"rifaximin-ssd","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1617","moleculeType":"Small molecule","molecularWeight":"785.89"},"_fixedAt":"2026-03-30T17:28:16.388531","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifaximin is a rifamycin-class antibiotic that acts locally in the gastrointestinal tract without systemic absorption. The SSD formulation (likely a sustained-release or modified delivery form) targets bacterial RNA polymerase to inhibit bacterial protein synthesis. This mechanism reduces pathogenic bacterial populations in the gut, potentially benefiting conditions driven by dysbiosis or bacterial overgrowth.","oneSentence":"Rifaximin SSD is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:23.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Traveler's diarrhea (approved indication for rifaximin)"},{"name":"Hepatic encephalopathy (approved indication for rifaximin)"},{"name":"Irritable bowel syndrome with diarrhea (IBS-D) — Phase 3 pipeline indication"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05297448","phase":"PHASE3","title":"Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-08-03","conditions":"Hepatic Encephalopathy","enrollment":466},{"nctId":"NCT05071716","phase":"PHASE3","title":"Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-04-07","conditions":"Hepatic Encephalopathy","enrollment":524},{"nctId":"NCT06718686","phase":"PHASE1, PHASE2","title":"Rifaximin SSD in Dementia Trial","status":"RECRUITING","sponsor":"Jasmohan Bajaj","startDate":"2024-12-30","conditions":"Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease","enrollment":20},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":"Overt Hepatic Encephalopathy","enrollment":71},{"nctId":"NCT01951209","phase":"NA","title":"Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis","status":"TERMINATED","sponsor":"David E. Kaplan, MD MSc","startDate":"2016-11-17","conditions":"Liver Cirrhosis, Chronic Hepatitis C","enrollment":13},{"nctId":"NCT01904409","phase":"PHASE2","title":"Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":420},{"nctId":"NCT02124512","phase":"PHASE2","title":"Blood Lipopolysaccharide (LPS) Rifaximin Study","status":"COMPLETED","sponsor":"Philip Kern","startDate":"2015-03","conditions":"Obese, Insulin Resistance, Metabolic Syndrome","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2023 Mar","pmid":"35750249","title":"Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.","journal":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rifaximin SSD","genericName":"Rifaximin SSD","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin SSD is a small molecule that inhibits bacterial DNA-directed RNA polymerase, classified as an inhibitor. It has been studied in clinical trials for various conditions, including dementia, liver cirrhosis, and hepatic encephalopathy, among others.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}